Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification

• Type: Article in International Scientific Journal
• Date: 2021

Authors

Soares, P (Author) FMUP; Povoa, AA (Author) Other; Melo, M (Author) Other; Vinagre, J (Author) Other; Maximo, V (Author) FMUP; Eloy, C (Author) Other; Cameselle Teijeiro, JM (Author) Other; Sobrinho Simoes, M (Author) Other

Journal

Title: Endocrine Pathology

ISSN: 1046-3976

Publisher: Springer Nature

Indexing

ISI Web of Knowledge - 23 Citations

Scopus - 26 Citations

Other information

Authenticus ID: P-00T-J9K

DOI: 10.1007/s12022-021-09666-1

Abstract (EN): This review addresses the impact of molecular alterations on the diagnosis and prognosis of differentiated thyroid carcinoma (DTC), including papillary, follicular, and well-differentiated carcinoma NOS, as well as oncocytic neoplasms. The molecular characterization of DTC is based upon the well-established dichotomy of BRAF-like and RAS-like designations, together with a remaining third group, less homogeneous, composed of non-BRAF-/non-RAS-like tumors. The role of BRAF V600E mutation in risk stratification is discussed in the clinico-pathological context, namely, staging and invasive features of classic papillary thyroid carcinoma (PTC) and histopathological variants carrying an excellent prognosis (microPTC) or a guarded prognosis, including the aggressive variants tall cell and hobnail cell PTCs. In follicular patterned tumors, namely, follicular thyroid carcinoma (FTC), with or without oncocytic features, the most prevalent molecular alteration are RAS mutations that do not carry prognostic significance. The only genetic alteration that has been proven to play a role in risk stratification of PTC and FTC is TERT promoter (TERTp) mutation.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 19